Literature DB >> 6086207

Marijuana effect and delta-9-tetrahydrocannabinol plasma level.

C W Chiang, G Barnett.   

Abstract

delta-9-Tetrahydrocannabinol (THC) kinetics and dynamics of self-reported psychologic "high" effect are analyzed in six subjects who smoked marijuana cigarettes of three different potencies. Correlation of the pharmacologic response to smoking a marijuana cigarette with plasma THC levels was done with compartmental models and phase plots. It was concluded that the effect compartment for psychologic high is directly coupled to the central (plasma) compartment. It was observed that effect is directly proportional to mean THC levels from approximately 1 to 4 hr after the start of smoking a marijuana cigarette.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6086207     DOI: 10.1038/clpt.1984.168

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  15 in total

1.  On the high road: driving under the influence of cannabis in Ontario.

Authors:  G W Walsh; R E Mann
Journal:  Can J Public Health       Date:  1999 Jul-Aug

Review 2.  The use of kinetic-dynamic interactions in the evaluation of drugs.

Authors:  D B Campbell
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

3.  The impact of arteriovenous concentration differences on pharmacodynamic parameter estimates.

Authors:  B Tuk; M Danhof; J W Mandema
Journal:  J Pharmacokinet Biopharm       Date:  1997-02

4.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

5.  Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics.

Authors:  Jules A A C Heuberger; Zheng Guan; Olubukayo-Opeyemi Oyetayo; Linda Klumpers; Paul D Morrison; Tim L Beumer; Joop M A van Gerven; Adam F Cohen; Jan Freijer
Journal:  Clin Pharmacokinet       Date:  2015-02       Impact factor: 6.447

Review 6.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships.

Authors:  Rebecca L Hartman; Timothy L Brown; Gary Milavetz; Andrew Spurgin; David A Gorelick; Gary Gaffney; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2015-08-10       Impact factor: 3.345

8.  Gaps in predicting clinical doses for cannabinoids therapy: Overview of issues for pharmacokinetics and pharmacodynamics modelling.

Authors:  Zheng Liu; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2018-06-07       Impact factor: 4.335

9.  Hippocampal neurotoxicity of Delta9-tetrahydrocannabinol.

Authors:  G C Chan; T R Hinds; S Impey; D R Storm
Journal:  J Neurosci       Date:  1998-07-15       Impact factor: 6.167

10.  Psychomotor performance, subjective and physiological effects and whole blood Δ⁹-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis.

Authors:  David M Schwope; Wendy M Bosker; Johannes G Ramaekers; David A Gorelick; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2012-05-15       Impact factor: 3.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.